A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Latest Information Update: 30 Dec 2024
At a glance
- Drugs Cisplatin (Primary) ; Nivolumab (Primary)
- Indications Oropharyngeal cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 13 Dec 2024 Planned End Date changed from 28 Feb 2025 to 11 Dec 2025.
- 08 Oct 2024 Status changed from suspended to active, no longer recruiting.
- 10 Nov 2023 Status changed from recruiting to suspended due to end of initial phase of multi-phase protocol.